The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2024

Filed:

May. 13, 2022
Applicant:

Jazz Pharmaceuticals Research Uk Limited, Kent, GB;

Inventors:

Geoffrey Guy, Cambridge, GB;

Stephen Wright, Altrincham, GB;

Orrin Devinsky, New York, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 31/5513 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01); A61P 25/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 31/5513 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01); A61P 25/08 (2018.01);
Abstract

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.


Find Patent Forward Citations

Loading…